Shanghai Pioneer (HKG:1345) expects a decline of between 45% to 48% in net profit for the first half of 2025 from 87.9 million yuan a year prior, a Tuesday filing with the Hong Kong bourse said.
The pharmaceutical products producer attributed the forecast to a significant drop in government grants received in the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.